Metabolic consequences of advanced chronic heart failure and its modification by implantation of a durable left ventricular assist device
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00085174" target="_blank" >RIV/00023001:_____/24:00085174 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10483477 RIV/00216208:11120/24:43927444
Result on the web
<a href="https://www.imrpress.com/journal/RCM/25/11/10.31083/j.rcm2511388/htm" target="_blank" >https://www.imrpress.com/journal/RCM/25/11/10.31083/j.rcm2511388/htm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.31083/j.rcm2511388" target="_blank" >10.31083/j.rcm2511388</a>
Alternative languages
Result language
angličtina
Original language name
Metabolic consequences of advanced chronic heart failure and its modification by implantation of a durable left ventricular assist device
Original language description
Heart failure (HF) is a clinical syndrome characterized by the inability of the heart to provide adequate perfusion to tissues and organs, resulting in typical symptoms such as fatigue, dyspnea, dyspepsia, or swelling due to decreased cardiac output. With its increasing prevalence, heart failure has become one of the leading causes of morbidity and mortality worldwide, imposing a significant burden on the population by reducing long-term life expectancy and raising hospital costs. Indeed, over 20 million people worldwide suffer from heart failure, with a 5-year mortality rate of 60–70%. As heart failure progresses, various structural and metabolic changes occur within the myocardium and organ systems. In the past two decades, therapeutic options for heart failure patients have significantly expanded. In addition to novel pharmacological treatment, advanced surgical methods such as heart transplantation (HTx) and the implantation of durable left ventricular assist devices (LVADs) are available for patients with end-stage heart failure. This review discusses the pathophysiological aspects and metabolic consequences of heart failure and metabolic changes, as well as the benefits and challenges of implanting a left ventricular assist device. Furthermore, future targets for heart failure diagnostics and therapy will be highlighted.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Reviews in cardiovascular medicine
ISSN
1530-6550
e-ISSN
2153-8174
Volume of the periodical
25
Issue of the periodical within the volume
11
Country of publishing house
CN - CHINA
Number of pages
12
Pages from-to
"art. no. 388"
UT code for WoS article
001368590300003
EID of the result in the Scopus database
2-s2.0-85210745156